Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia

Haematologica

Volumn 88, Issue 11, 2003, Pages 1213-1220

  Sureda, Anna ^a   Carrasco, Marina ^a   De Miguel, Miguel ^b   Martínez, Jesùs A ^c   Conde, Eulogio ^d   Sanz, Miguel A ^c   Díaz Mediavilla, Joaquin ^b   Sierra, Jorge ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Blast crisis; Chronic myelold leukemia; STI571

Indexed keywords

IMATINIB;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD TOXICITY; CANCER REGRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HUMAN; KARYOTYPE; LIVER TOXICITY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; MUSCLE CRAMP; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PHILADELPHIA 1 CHROMOSOME; PROGNOSIS; SKIN TOXICITY; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BLAST CRISIS; DISEASE-FREE SURVIVAL; ENZYME INHIBITORS; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEUTROPENIA; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0344823969     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia: a concise update. Blood 1993;82:691-703.
2. Kantarjian HM, O'Brien S, Anderlini P, Talpaz M. Treatment of chronic myelogenous leukemia: current status and investigational options. Blood 1996;87:3069-81.
3. Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999;131:207-19.
4. Sacchi S, Kantarjian HM, O'Brien S, Cortes J, Rios MB, Giles FJ, et al. Chronic myelogenous leukemia in nonlymphoid blastic phase. Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 1999;86:2632-41.
5. Horowitz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1996;17:S5-S6.
6. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
7. Beran M, Cao X, Estrov Z, Jeha S, Jin G, O'Brien S, et al. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57184). Clin Cancer Res 1998;4:1661-72.
8. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
9. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
10. Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002;99:3547-53.
11. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99:3530-9.
12. Wadhwa J, Szydlo RM, Apperley JF, Chase A, Bua M, Marin D, et al. Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. Blood 2002;99:2304-9.
13. Vidal D, Puig L, Sureda A, Alomar A. STI571-induced Stevens-Johnson syndrome. Br J Haematol 2002;119:274-5.
14. Lahaye T, Kreil S, Schoch C. Prognostic impact of immunophenotype, karyotypic evolution, and type of BCR-ABL fusion transcripts in patients with myeloid blast crisis treated with STI571 (Glivec). Blood 2001;98:138a[abstract 580].
15. Tsao AS, Kantarjian H, Talpaz M. STI-571 in chronic myelogenous leukaemia. Br J Haematol 2002;119:15-24.
16. le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000;95:1758-66.
17. Weisber E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cells. Blood 2000;95:3498-505.
18. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000;96:1070-9.
19. Gambacorti-Passerini C, Barni R, le Coutre P, Zucchetti M, Cabrita G, Cleris L, et al. Role of a 1 acid glycoprotein in the in vivo resistance of human BCR-ABL + leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 2000;92:1641-50.
20. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80.
21. Barthe C, Cony-Makhoul P, Melo JV. Roots of clinical resistance to STI-571 cancer therapy. Science 2001;293: [abstract 2163].
22. Peters DG, Hoover RR, Gerlach MJ, Koh EY, Zhang H, Choe K, et al. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood 2001;97:1404-12.
23. 2 enhances selective cytotoxic effects on STI-571 against Bcr-Abl positive acute leukemia cells. Leukemia 2001;15:772-8.